INVOKAMET XR Drug Patent Profile
✉ Email this page to a colleague
When do Invokamet Xr patents expire, and what generic alternatives are available?
Invokamet Xr is a drug marketed by Janssen Pharms and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and nineteen patent family members in forty-five countries.
The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Invokamet Xr
Invokamet Xr was eligible for patent challenges on March 29, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 26, 2029. This may change due to patent challenges or generic licensing.
There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INVOKAMET XR?
- What are the global sales for INVOKAMET XR?
- What is Average Wholesale Price for INVOKAMET XR?
Summary for INVOKAMET XR
| International Patents: | 219 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 2 |
| Drug Prices: | Drug price information for INVOKAMET XR |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for INVOKAMET XR |
| DailyMed Link: | INVOKAMET XR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INVOKAMET XR
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for INVOKAMET XR
| Drug Class | Biguanide Sodium-Glucose Cotransporter 2 Inhibitor |
| Mechanism of Action | P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors |
Paragraph IV (Patent) Challenges for INVOKAMET XR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| INVOKAMET XR | Extended-release Tablets | canagliflozin; metformin hydrochloride | 50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg | 205879 | 1 | 2018-11-21 |
US Patents and Regulatory Information for INVOKAMET XR
INVOKAMET XR is protected by eleven US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of INVOKAMET XR is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting INVOKAMET XR
Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS
Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-004 | Sep 20, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-004 | Sep 20, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INVOKAMET XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-002 | Sep 20, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-003 | Sep 20, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-004 | Sep 20, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INVOKAMET XR
When does loss-of-exclusivity occur for INVOKAMET XR?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 4099
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(BETA-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
Patent: 7510
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO Y PROCESO PARA LA PREPARACIÓN
Estimated Expiration: ⤷ Sign Up
Patent: 8450
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 07329895
Patent: Crystalline form of 1- (beta-D-glucopyranosyl) -4 -methyl- 3- [5- (4 -fluorophenyl) -2-thienylmethyl] benzene hemihydrate
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0718882
Patent: FORMA CRISTALINA DE HEMI-HIDRATO DE 1-(BETA-D-GLICOPIRANOSIL)-4-METIL-3-[5-(4-FLUORFENIL)-2-TI ENILMETIL]BENZENO
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 71357
Patent: FORME CRISTALLINE DE 1- (.BETA.-D-GLUCOPYRANOSYL)-4 -METHYLE-2-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYLE] BENZENE HEMIHYDRATE (CRYSTALLINE FORM OF 1- (.BETA.-D-GLUCOPYRANOSYL)-4-METHYL-2-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE HEMIHYDRATE)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 07003487
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO, INHIBIDOR DEL TRANSPORTADOR DE GLUCOSA SODIO-DEPENDIENTE; PROCESO DE PREPARACION; COMPOSICION FARMACEUTICA, UTIL PARA EL TRATAMIENTO DE DIA
Estimated Expiration: ⤷ Sign Up
China
Patent: 1573368
Patent: Crystalline form of 1- (belta-D-glucopyranosyl) -4 -methyl- 3- [5- (4 -fluorophenyl) -2-thienylmethyl] benzene hemihydrate
Estimated Expiration: ⤷ Sign Up
Patent: 2675299
Patent: Crystalline form of 1- (beta-D-glucopyranosyl) -4 -methyl- 3- [5- (4 -fluorophenyl) -2-thienylmethyl] benzene hemihydrate
Estimated Expiration: ⤷ Sign Up
Patent: 2675380
Patent: Crystalline form of 1- (beta-D-glucopyranosyl) -4 -methyl- 3- [5- (4 -fluorophenyl) -2-thienylmethyl] benzene hemihydrate
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 10719
Patent: FORMA CRIATALINA DEL HEMIHIDRATO DE 1-(BETA-DGLUCOPIRANOSIL )-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 861
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B-D GLUCOPIRANOSIL)-4-METIL-3[5-(4-FLUOROFENIL)-2-TIENILMETIL] BENCENO
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0140254
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 14969
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 02224
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 099489
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(?-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
El Salvador
Patent: 09003285
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(BETA-D-GLUCOPIRANOSIL)-4-METIL-3-[ 5-(4-FLUOROFENIL)-2- TIENILMETIL] BENCENO
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 7103
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА ГЕМИГИДРАТА 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА (CRYSTALLINE FORM OF 1-(&bgr;-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE HEMIHYDRATE)
Estimated Expiration: ⤷ Sign Up
Patent: 0970540
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА ГЕМИГИДРАТА 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 02224
Patent: FORME CRISTALLINE DE 1- (ß-D-GLUCOPYRANOSYL) -4 -MÉTHYLE- 3- [5- (4 -FLUOROPHÉNYL) -2-THIÉNYLMÉTHYLE]BENZÈNE HÉMIHYDRATE (CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE)
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 0900151
Patent: FORMA CRISTALINA DE 1-(B-D-GLUCOPIRANOSIL) -4-METIL-3-[5-4--FLUOROFENIL)-2-TIENILMETIL] HEMIDRATO DE BENCENO
Estimated Expiration: ⤷ Sign Up
Honduras
Patent: 09001135
Patent: FORMA CRISTALINAS DEL HEMIHIDRATO DE 1-(B-D-GLUCOPIRANOSIL)- 4-METIL,3-{5-(4-FLUOROFENIL)-2-TIENILMETIL} BENCENO
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 9032
Patent: CRYSTALLINE HEMIHYDRATE OF 1-(BETA-D--GLUCOPYRANOSTYL) -4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL BENZENE AND COMPOSITIONS COMPRISING THE SAME
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 59788
Estimated Expiration: ⤷ Sign Up
Patent: 10511602
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 3702
Patent: CRYSTALLINE FORM OF 1-(B-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE HEMIHYDRATE
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 09005857
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(BETA-D-GLUCOPIRANOSIL)-4-ME TIL-3[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO. (CRYSTALLINE FORM OF 1- (β-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL] BENZENE HEMIHYDRATE.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 829
Patent: KRISTALNI OBLIK 1-(β-D-GLUKOPIRANOZIL) -4-METIL- 3-[5- (4-FLUORFENIL)-2-TIENILMETIL]BENZEN HEMIHIDRAT (CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 7545
Patent: CRYSTALLINE FORM OF 1- (BETA-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL] BENZENE HEMIHYDRATE
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 0900113
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(Beta-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL] BENCENO.
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 4354
Estimated Expiration: ⤷ Sign Up
Patent: 091778
Estimated Expiration: ⤷ Sign Up
Panama
Patent: 59401
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 081201
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
Patent: 110841
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
Patent: 130591
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 02224
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 02224
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 274
Patent: KRISTALNI OBLIK 1-(β-D-GLUKOPIRANOZIL)-4-METIL-3-[5-(4-FLUORFENIL)-2-TIENILMETIL]BENZEN HEMIHIDRAT (CRYSTALLINE FORM OF 1- (SS-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 02224
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0903941
Patent: Crystalline form of 1- (Beta-D-Glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene hemihydrate
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1146095
Estimated Expiration: ⤷ Sign Up
Patent: 090086282
Patent: CRYSTALLINE FORM OF 1-(beta;-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE HEMIHYDRATE
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 56640
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 03325
Estimated Expiration: ⤷ Sign Up
Patent: 0829259
Patent: Crystalline form of 1-(&bgr;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 135
Patent: КРИСТАЛІЧНА ФОРМА ГЕМІГІДРАТУ 1-(β-D-ГЛЮКОПІРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНІЛ)-2-ТІЕНІЛМЕТИЛ]БЕНЗОЛУ[КРИСТАЛЛИЧЕСКАЯ ФОРМА ГЕМИГИДРАТА 1-(b-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЭНИЛМЕТИЛ]БЕНЗОЛА (CRYSTALLINE FORM OF 1-(в-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE HEMIHYDRATE)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 730
Patent: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B (BETA)-D-GLUCOPIRANOSIL) -4-METIL-3-[5-(4-FLUOROFENIL) -2-TIENILMETIL]BENCENO
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering INVOKAMET XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 200603881 | Substituted fused heterocyclic C-glycosides | ⤷ Sign Up |
| South Korea | 20090086282 | CRYSTALLINE FORM OF 1-(beta;-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE HEMIHYDRATE | ⤷ Sign Up |
| Ukraine | 83377 | N-ГЛИКОЗИД, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ;N-ГЛІКОЗИД, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ (N- GLYCOSIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INVOKAMET XR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1651658 | 14C0034 | France | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119 |
| 1651658 | CR 2014 00024 | Denmark | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119 |
| 1651658 | CA 2014 00024 | Denmark | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
